Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose adalimumab in Chinese patients with rheumatoid arthritis
ChiCTR2200058839Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab in rheumatoid arthritis (RA) (4 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Recurrence rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2200058839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058839.